Zepbound helped patients lose more weight than a major rival in a head-to-head trial
Eli Lilly & Co. Inc.'s stock (LLY) rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.
Zepbound achieved an average weight loss of 20.2% at 72 weeks in adults living with obesity without diabetes, compared with just 13.7% for Wegovy, the company said in a statement.
Zepbound is a dual GIP and GLP-1 receptor agonist, while Wegovy is a mono GLP-1 receptor agonist, where GIP and GLP are hormones that lower blood sugar levels and slow digestion.
The two drugs are part of a new class used to manage diabetes and treat obesity, and have become so popular they have created shortages.
Participants taking Zepbound lost 50.3 pounds at 72 weeks, while participants taking Wegovy lost just 33.1 pounds. The trial enrolled 751 participants across the U.S. and Puerto Rico.
"Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice," Dr. Leonard C. Glass, senior VP of global medical affairs at Lilly Cardiometabolic Health said in prepared remarks.
In a secondary endpoint, people taking Zepbound achieved at least 25% body-weight loss compared with 16.1% taking Wegovy.
Zepbound's safety profile was similar to previous trials with the most common adverse event for both treatments being gastrointestinal-related and generally mild-to-moderate in severity.
Zepbound is marketed as Mounjaro as a treatment for diabetes in some markets.
Lilly plans to continue its analysis of the results, which will also be published in a peer-reviewed journal and presented at a medical meeting in 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.